Evidence of microangiopathic hemolytic anemia (MHA) was found in 14 of 22 patients with malignant phase hypertension, and in one of these, a patient with proliferative glomerulonephritis, MHA and malignant hypertension developed together during a three-month period of observation.Among 61 rats subjected to unilateral nephrectomy, injected with DOCA, and given 1% saline to drink, 42 developed evidence of MHA, Eighty-four per cent of these also had fibrinoid necrosis and/ or plasmatic vasculosis in the remaining kidney at autopsy. Blood pressure rose to 150 mm Hg or more in 72% of these DOCA-injected animals. In 29 control rats subjected to unilateral nephrectomy only, blood pressure rose to 150 mm Hg or more in 2135, MHA developed in 14%, and fibrinoid lesions were found in none.The significance of these observations is discussed in relation to the possibility that MHA is either a consequence of malignant hypertension or a contributory factor in its pathogenesis.
KEY WORDSmicroangiopathic hemolytic anemia DOCA malignant hypertension fibrinoid lesions bilateral nephrectomy renal failure intravascular coagulation glomerulonephritis• An association between malignant phase hypertension and microangiopathic hemolytic anemia (MHA) is now well recognized. 1 "
5Since the association appears relatively common and since MHA, when it occurs in other states, is characterized by features similar to those of malignant hypertension, it seemed possible to us that MHA might at least contribute to the development of the malignant phase. 6 If this is so, MHA should be demonstrable when (or before) the malignant phase appears. Our earlier studies threw little light on this particular question since, by the time most patients presented, both the conditions were well established.